Bahar Ramezanpour holds a Ph.D. in disruptive innovation by genetically modified technologies from the University of Amsterdam and Erasmus University of Rotterdam under the supervision of Prof. Ab Osterhaus and dr. Eric Claassen.
She joined HUB in 2017 with a background in MPA, infectious diseases and genetically modified vaccines. Prior to joining HUB, she served as Director Business Development at ViroNovative B.V. and Sovalacc B.V., biotechnology company and life sciences consultancy respectively. In these positions, she was responsible for all the aspects of business development, including out-licensing and alliance management. Furthermore, she has been involved in the start-up and growth of several business ventures in the life sciences sector.